Zepbound vs. Wegovy: Which Is Right for You?

Two brands, one decision

Walk into any conversation about weight-loss medication and you will hear the two names traded as if they were interchangeable: Zepbound and Wegovy. They are not the same drug, and — as of the first trial that put them in the same room — they no longer post the same result. But the honest version of "which is right for you" refuses to end at the bigger number. For a mother, the answer is also written in side effects, in the monthly cost, in whether you are nursing or planning to be, and in a birth-control warning that applies to one of these drugs and not the other.

Start with the names, because they cause more confusion than anything else. Zepbound is tirzepatide. Wegovy is semaglutide. Both are FDA-approved, once-weekly injections for weight loss. The same two molecules are sold under different brands — Mounjaro (tirzepatide) and Ozempic (semaglutide) — for type 2 diabetes. Same medicine, different label, different indication. When a friend says her sister is "on Ozempic for weight loss," she almost certainly means the semaglutide family; the weight-loss brand is Wegovy.

The head-to-head, at last

For years the comparison leaned on separate trials run at different times on different people — a statistician's nightmare and a marketer's playground. That changed with SURMOUNT-5, the first trial to randomize people directly to one drug or the other. Over 72 weeks, adults with obesity took either tirzepatide or semaglutide at their maximum tolerated dose. Average weight change was −20.2% with tirzepatide versus −13.7% with semaglutide, and tirzepatide was declared superior on both weight and waist circumference¹.

That result does not float free of the rest of the evidence — it rhymes with each drug's own pivotal obesity trial. Semaglutide produced roughly 15% average weight loss in STEP 1²; tirzepatide reached close to 20% at the top dose in SURMOUNT-1³. Three separate lines of evidence point the same direction, which is what turns a single headline into something you can actually lean on.

Here is the caveat that no headline prints, and that this magazine will always print: "more on average" is a fact about groups, not about you. Plenty of women lose a great deal on semaglutide, tolerate it far better, or simply pay less for it. The trial tells you where the averages sit. It cannot tell you where a single mother's body will land.

Side effects: the same family, mostly at dose changes

Both drugs work through GLP-1 signaling; Zepbound adds a second gut hormone, GIP. Because the machinery overlaps, the side-effect profile does too. Gastrointestinal effects — nausea, diarrhea, constipation, vomiting — are the most common with both, most are mild to moderate, and they cluster during the weeks you are increasing the dose rather than at a settled maintenance dose¹.

There is no reliably "gentle" option here. Tolerance is individual, and the variable that matters more than the brand is the program: one that titrates slowly, checks in when the nausea spikes, and is willing to switch molecules if the first one does not sit well. A brand name cannot do any of that. A clinician can.

Staying there: the maintenance question a mother should ask first

Weight loss that reverses the moment you stop is not the goal — and this is exactly where a mother's-eye view earns its keep, because motherhood comes with planned pauses. Both drugs are studied as ongoing treatments, not courses you finish. When semaglutide was stopped and swapped for placebo in STEP 4, much of the lost weight returned⁴. Continuing tirzepatide in SURMOUNT-4 held the reduction, where stopping it gave much of it back⁵.

If there is any chance you will pause treatment — for a pregnancy, for a deployment, for a stretch when the budget cannot stretch — then "what happens when I stop, and how do I restart" is a more useful question than "which number is bigger." We walk through that whole arc in our guide to coming off a GLP-1 and the rebound question.

Cost and access

Zepbound is frequently priced higher than Wegovy, and a formal US cost-effectiveness analysis built directly on the SURMOUNT-5 results examined that value trade-off head-on⁶. Both manufacturers run savings programs, both come as fixed-dose pens, and the real-world availability of each has swung with shortages. For most mothers, though, the deciding number is not the list price on a press release — it is what your insurance covers and what actually leaves your account each month, a figure that only climbs as the dose does. Our column on the true cost as the dose climbs is worth reading before you fix on a molecule.

It is also worth knowing that the brand question and the compounded question are different questions. Neither Zepbound nor Wegovy is available as a low-cost compounded vial — those are the same molecules made by compounding pharmacies, which we weigh against the brands in compounded vs. brand on a family budget.

The mother-specific differences a brand comparison skips

Two facts belong in this decision that a straight efficacy chart leaves out entirely.

• Birth control. The Zepbound label carries an explicit warning that oral hormonal contraceptives may become less effective, and advises switching to a non-oral method or adding a barrier method around starting the drug and around each dose increase⁷. The Wegovy labeling does not carry that specific warning⁸. If you rely on the pill, that is not a footnote — it is a genuine, practical difference between the two drugs, and we unpack it in full in GLP-1s and birth control.
• Breastfeeding and pregnancy timing. Both are off the table during pregnancy and while nursing, and both linger roughly a week per dose, so the washout arithmetic is broadly similar. If you are nursing or planning to conceive, the timing plan matters more than the molecule — bring it to the conversation you have with your OB first.

So — which is right for you?

The averages favor Zepbound. Averages are not mothers. Tolerance, cost, what your plan covers, whether you take an oral contraceptive, and your pregnancy plans all feed a real decision — and the best programs can switch molecules when the first one is not the fit. That flexibility, under genuine clinical oversight, is exactly what our Editors' Rating methodology rewards, which is why a flat-priced, both-molecules, clinician-led program like CoreAge Rx sits at the top of our board of GLP-1 programs for moms — it can start you on either molecule and move you without resetting the budget. If cost is the deciding axis, our board of the most affordable programs sorts on exactly that. Pick a program that can adapt, then decide the molecule with a clinician who knows your history — not from a brand name on a billboard. This feature is educational only and is not medical advice.